The Japan Patent Office allowed claims covering novel aspects of Dyadic’s proprietary Thermothelomyces heterothallica recombinant protein expression technology. This milestone adds significant protection to the Company’s expanding global intellectual property portfolio and reinforces the strength of Dyadic’s differentiated C1 and Dapibus™ microbial production platforms.

"This patent represents an important milestone in our strategy to expand Dyadic’s intellectual property position and commercial opportunities in one of the world’s most advanced biotechnology markets," said Joe Hazelton, Dyadic’s President and Chief Operating Officer.

As part of its international growth strategy, Dyadic engaged Intralink, a leading international business development and market expansion firm, to support expansion efforts in Japan and other key markets. These efforts have generated targeted engagement opportunities with prospective partners, customers, and collaborators across the biotechnology, pharmaceutical, food, nutrition, life sciences, cosmetics, and industrial sectors. Mr. Hazelton is scheduled to meet with several high-potential existing and prospective partners during a business development visit in early July.

Japan is a strategic market for Dyadic, recognized for its leadership in regenerative medicine, biologics manufacturing, precision fermentation, advanced bioprocessing, biopharmaceuticals, cosmetics, food and nutrition technologies, and life sciences innovation. The Company believes its enhanced intellectual property protection, Intralink’s local business development support, and planned in-country engagements position Dyadic to capitalize on growing demand for scalable recombinant protein solutions.

"As we continue transforming Dyadic into a recombinant protein solutions company, expanding our presence in key global biotechnology markets is an important component of our long-term growth strategy," added Mr. Hazelton. "Our collaboration with Intralink has accelerated business development efforts in Japan and helped establish meaningful discussions with organizations seeking flexible, scalable, and cost-effective protein production solutions."

Dyadic’s proprietary C1 and Dapibus™ expression platforms are designed to enable rapid, scalable, and cost-effective production of recombinant proteins across multiple high-growth markets. Through commercial products, technology licensing, custom development, and strategic collaborations, the Company supports customers developing applications ranging from life sciences, food and nutrition, cosmetics to industrial enzymes, vaccines, monoclonal antibodies, and other biologics.

Dyadic believes its strengthened intellectual property portfolio, expanding commercial capabilities, growing network of strategic partners, and increasing international business development activities position the Company to address rising growing global demand for recombinant protein and support its long-term growth strategy.